메뉴 건너뛰기




Volumn 24, Issue 7, 2014, Pages 689-697

Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials

Author keywords

DPP 4 inhibitors; Heart failure; Meta analysis

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDE;

EID: 84901926135     PISSN: 09394753     EISSN: 15903729     Source Type: Journal    
DOI: 10.1016/j.numecd.2014.01.017     Document Type: Article
Times cited : (176)

References (60)
  • 1
    • 84866268783 scopus 로고    scopus 로고
    • Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    • Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
    • (2012) Diabetes Care , vol.35 , Issue.6 , pp. 1364-1379
    • Inzucchi, S.E.1    Bergenstal, R.M.2    Buse, J.B.3    Diamant, M.4    Ferrannini, E.5    Nauck, M.6
  • 2
    • 84883745765 scopus 로고    scopus 로고
    • Alogliptin after acute coronary syndrome in patients with type 2 diabetes
    • EXAMINE Investigators
    • White W.B., Cannon C.P., Heller S.R., Nissen S.E., Bergenstal R.M., Bakris G.L., EXAMINE Investigators, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327-1335.
    • (2013) N Engl J Med , vol.369 , pp. 1327-1335
    • White, W.B.1    Cannon, C.P.2    Heller, S.R.3    Nissen, S.E.4    Bergenstal, R.M.5    Bakris, G.L.6
  • 3
    • 84883765959 scopus 로고    scopus 로고
    • SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
    • Scirica B.M., Bhatt D.L., Braunwald E., Steg P.G., Davidson J., Hirshberg B., et al. SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326.
    • (2013) N Engl J Med , vol.369 , pp. 1317-1326
    • Scirica, B.M.1    Bhatt, D.L.2    Braunwald, E.3    Steg, P.G.4    Davidson, J.5    Hirshberg, B.6
  • 6
    • 0028659004 scopus 로고
    • Operating characteristics of a rank correlation test for publication bias
    • Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101.
    • (1994) Biometrics , vol.50 , Issue.4 , pp. 1088-1101
    • Begg, C.B.1    Mazumdar, M.2
  • 7
    • 0030922816 scopus 로고    scopus 로고
    • Bias in meta-analysis detected by a simple, graphical test
    • Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
    • (1997) BMJ , vol.315 , Issue.7109 , pp. 629-634
    • Egger, M.1    Davey Smith, G.2    Schneider, M.3    Minder, C.4
  • 8
    • 69149107165 scopus 로고    scopus 로고
    • PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
    • W64
    • Moher D., Liberati A., Tetzlaff J., Altman D.G. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264-269. W64.
    • (2009) Ann Intern Med , vol.151 , Issue.4 , pp. 264-269
    • Moher, D.1    Liberati, A.2    Tetzlaff, J.3    Altman, D.G.4
  • 9
    • 84901943115 scopus 로고    scopus 로고
    • On behalf of the SAVOR-TIMI 53 Steering Committee and Investigators
    • Outcomes of patients with type 2 diabetes and known congestive heart failure treated with saxagliptin: Analyses of the SAVOR-TIMI 53 Study. Poster number 5082 presented at American Heart Association, Dallas, Texas, USA on 17th November 2013.
    • Scirica BM, Raz I, Cavender MA, Steg PG, Hirshberg B, Davidson J, etal., on behalf of the SAVOR-TIMI 53 Steering Committee and Investigators. Outcomes of patients with type 2 diabetes and known congestive heart failure treated with saxagliptin: Analyses of the SAVOR-TIMI 53 Study. Poster number 5082 presented at American Heart Association 2013, Dallas, Texas, USA on 17th November 2013.
    • (2013)
    • Scirica, B.M.1    Raz, I.2    Cavender, M.A.3    Steg, P.G.4    Hirshberg, B.5    Davidson, J.6
  • 10
    • 33845293219 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
    • Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699.
    • (2006) J Card Fail , vol.12 , pp. 694-699
    • Sokos, G.G.1    Nikolaidis, L.A.2    Mankad, S.3    Elahi, D.4    Shannon, R.P.5
  • 11
    • 28144441354 scopus 로고    scopus 로고
    • Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
    • Nikolaidis L.A., Elahi D., Shen Y.T., Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289:H2401-H2408.
    • (2005) Am J Physiol Heart Circ Physiol , vol.289
    • Nikolaidis, L.A.1    Elahi, D.2    Shen, Y.T.3    Shannon, R.P.4
  • 12
    • 84860390563 scopus 로고    scopus 로고
    • A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
    • Read P.A., Hoole S.P., White P.A., Khan F.Z., O'Sullivan M., West N.E., et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011, 4(3):266-272.
    • (2011) Circ Cardiovasc Interv , vol.4 , Issue.3 , pp. 266-272
    • Read, P.A.1    Hoole, S.P.2    White, P.A.3    Khan, F.Z.4    O'Sullivan, M.5    West, N.E.6
  • 13
    • 77951934948 scopus 로고    scopus 로고
    • DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease
    • Read P.A., Khan F.Z., Heck P.M., Hoole S.P., Dutka D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010, 3:195-201.
    • (2010) Circ Cardiovasc Imaging , vol.3 , pp. 195-201
    • Read, P.A.1    Khan, F.Z.2    Heck, P.M.3    Hoole, S.P.4    Dutka, D.P.5
  • 14
    • 77950267745 scopus 로고    scopus 로고
    • Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor
    • Ban K., Kim K.H., Cho C.K., Sauvé M., Diamandis E.P., Backx P.H., et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151:1520-1531.
    • (2010) Endocrinology , vol.151 , pp. 1520-1531
    • Ban, K.1    Kim, K.H.2    Cho, C.K.3    Sauvé, M.4    Diamandis, E.P.5    Backx, P.H.6
  • 15
    • 58149335320 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
    • Pratley R.E., Kipnes M.S., Fleck P.R., Wilson C., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Obes Metab 2009, 11:167-176.
    • (2009) Obes Metab , vol.11 , pp. 167-176
    • Pratley, R.E.1    Kipnes, M.S.2    Fleck, P.R.3    Wilson, C.4    Mekki, Q.5
  • 16
    • 58149171060 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study
    • DeFronzo R.A., Fleck P.R., Wilson C.A., Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008, 31:2315-2317.
    • (2008) Diabetes Care , vol.31 , pp. 2315-2317
    • DeFronzo, R.A.1    Fleck, P.R.2    Wilson, C.A.3    Mekki, Q.4
  • 17
    • 57649225147 scopus 로고    scopus 로고
    • Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
    • Alogliptin Study 008 Group
    • Nauck M.A., Ellis G.C., Fleck P.R., Wilson C.A., Mekki Q., Alogliptin Study 008 Group Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract 2009, 63(1):46-55.
    • (2009) Int J Clin Pract , vol.63 , Issue.1 , pp. 46-55
    • Nauck, M.A.1    Ellis, G.C.2    Fleck, P.R.3    Wilson, C.A.4    Mekki, Q.5
  • 18
    • 84901948754 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/.
  • 19
    • 79951699944 scopus 로고    scopus 로고
    • Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes
    • Rosenstock J., Inzucchi S.E., Seufert J., Fleck P.R., Wilson C.A., Mekki Q. Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. Diabetes Care 2010, 33(11):2406-2408.
    • (2010) Diabetes Care , vol.33 , Issue.11 , pp. 2406-2408
    • Rosenstock, J.1    Inzucchi, S.E.2    Seufert, J.3    Fleck, P.R.4    Wilson, C.A.5    Mekki, Q.6
  • 20
    • 79953174825 scopus 로고    scopus 로고
    • Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
    • Gomis R., Espadero R.M., Jones R., Woerle H.J., Dugi K.A. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13(7):653-661.
    • (2011) Diabetes Obes Metab , vol.13 , Issue.7 , pp. 653-661
    • Gomis, R.1    Espadero, R.M.2    Jones, R.3    Woerle, H.J.4    Dugi, K.A.5
  • 21
    • 78649691630 scopus 로고    scopus 로고
    • Safety and efficacy of linagliptin as add- on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
    • Taskinen M.R., Rosenstock J., Tamminen I., Kubiak R., Patel S., Dugi K.A., et al. Safety and efficacy of linagliptin as add- on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011, 13:65-74.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 65-74
    • Taskinen, M.R.1    Rosenstock, J.2    Tamminen, I.3    Kubiak, R.4    Patel, S.5    Dugi, K.A.6
  • 22
    • 78851472527 scopus 로고    scopus 로고
    • Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
    • Del Prato S., Barnett A.H., Huisman H., Neubacher D., Woerle H.J., Dugi K.A. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011, 13(3):258-267.
    • (2011) Diabetes Obes Metab , vol.13 , Issue.3 , pp. 258-267
    • Del Prato, S.1    Barnett, A.H.2    Huisman, H.3    Neubacher, D.4    Woerle, H.J.5    Dugi, K.A.6
  • 23
    • 80053072352 scopus 로고    scopus 로고
    • Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study
    • Owens D.R., Swallow R., Dugi K.A., Woerle H.J. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011, 28(11):1352-1361.
    • (2011) Diabet Med , vol.28 , Issue.11 , pp. 1352-1361
    • Owens, D.R.1    Swallow, R.2    Dugi, K.A.3    Woerle, H.J.4
  • 24
    • 84862813117 scopus 로고    scopus 로고
    • Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
    • Haak T., Meinicke T., Jones R., Weber S., von Eynatten M., Woerle H.J. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2012, 14(6):565-574.
    • (2012) Diabetes Obes Metab , vol.14 , Issue.6 , pp. 565-574
    • Haak, T.1    Meinicke, T.2    Jones, R.3    Weber, S.4    von Eynatten, M.5    Woerle, H.J.6
  • 25
    • 84858003503 scopus 로고    scopus 로고
    • Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study
    • Kawamori R., Inagaki N., Araki E., Watada H., Hayashi N., Horie Y., et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012, 14(4):348-357.
    • (2012) Diabetes Obes Metab , vol.14 , Issue.4 , pp. 348-357
    • Kawamori, R.1    Inagaki, N.2    Araki, E.3    Watada, H.4    Hayashi, N.5    Horie, Y.6
  • 26
    • 84864757433 scopus 로고    scopus 로고
    • 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
    • Gallwitz B., Rosenstock J., Rauch T., Bhattacharya S., Patel S., von Eynatten M., et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012, 380(9840):475-483.
    • (2012) Lancet , vol.380 , Issue.9840 , pp. 475-483
    • Gallwitz, B.1    Rosenstock, J.2    Rauch, T.3    Bhattacharya, S.4    Patel, S.5    von Eynatten, M.6
  • 27
    • 79955015666 scopus 로고    scopus 로고
    • Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
    • CV181039 Investigators
    • Pfützner A., Paz-Pacheco E., Allen E., Frederich R., Chen R., CV181039 Investigators Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011, 13(6):567-576.
    • (2011) Diabetes Obes Metab , vol.13 , Issue.6 , pp. 567-576
    • Pfützner, A.1    Paz-Pacheco, E.2    Allen, E.3    Frederich, R.4    Chen, R.5
  • 28
    • 81255160603 scopus 로고    scopus 로고
    • Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial
    • Yang W., Pan C.Y., Tou C., Zhao J., Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract 2011, 94(2):217-224.
    • (2011) Diabetes Res Clin Pract , vol.94 , Issue.2 , pp. 217-224
    • Yang, W.1    Pan, C.Y.2    Tou, C.3    Zhao, J.4    Gause-Nilsson, I.5
  • 29
    • 84863230449 scopus 로고    scopus 로고
    • Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial
    • Pan C.Y., Yang W., Tou C., Gause-Nilsson I., Zhao J. Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev 2012, 28(3):268-275.
    • (2012) Diabetes Metab Res Rev , vol.28 , Issue.3 , pp. 268-275
    • Pan, C.Y.1    Yang, W.2    Tou, C.3    Gause-Nilsson, I.4    Zhao, J.5
  • 30
    • 70349333861 scopus 로고    scopus 로고
    • Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
    • CV181-011 Study Investigators
    • Rosenstock J., Aguilar-Salinas C., Klein E., Nepal S., List J., Chen R., CV181-011 Study Investigators Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin 2009, 25(10):2401-2411.
    • (2009) Curr Med Res Opin , vol.25 , Issue.10 , pp. 2401-2411
    • Rosenstock, J.1    Aguilar-Salinas, C.2    Klein, E.3    Nepal, S.4    List, J.5    Chen, R.6
  • 31
    • 79959217544 scopus 로고    scopus 로고
    • Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
    • CV181013 Investigators
    • Hollander P.L., Li J., Frederich R., Allen E., Chen R., CV181013 Investigators Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2011, 8(2):125-135.
    • (2011) Diab Vasc Dis Res , vol.8 , Issue.2 , pp. 125-135
    • Hollander, P.L.1    Li, J.2    Frederich, R.3    Allen, E.4    Chen, R.5
  • 32
    • 79959211974 scopus 로고    scopus 로고
    • Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
    • CV181040 Investigators
    • Chacra A.R., Tan G.H., Ravichandran S., List J., Chen R., CV181040 Investigators Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011, 8(2):150-159.
    • (2011) Diab Vasc Dis Res , vol.8 , Issue.2 , pp. 150-159
    • Chacra, A.R.1    Tan, G.H.2    Ravichandran, S.3    List, J.4    Chen, R.5
  • 33
    • 79954508355 scopus 로고    scopus 로고
    • Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    • Barzilai N., Guo H., Mahoney E.M., Caporossi S., Golm G.T., Langdon R.B., et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 2011, 27(5):1049-1058.
    • (2011) Curr Med Res Opin , vol.27 , Issue.5 , pp. 1049-1058
    • Barzilai, N.1    Guo, H.2    Mahoney, E.M.3    Caporossi, S.4    Golm, G.T.5    Langdon, R.B.6
  • 34
    • 34547863123 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
    • Sitagliptin Study 035 Group
    • Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P., Sitagliptin Study 035 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9(5):733-745.
    • (2007) Diabetes Obes Metab , vol.9 , Issue.5 , pp. 733-745
    • Hermansen, K.1    Kipnes, M.2    Luo, E.3    Fanurik, D.4    Khatami, H.5    Stein, P.6
  • 35
    • 78751562877 scopus 로고    scopus 로고
    • Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes
    • Yoon K.H., Shockey G.R., Teng R., Golm G.T., Thakkar P.R., Meehan A.G., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetes. Int J Clin Pract 2011, 65:154-164.
    • (2011) Int J Clin Pract , vol.65 , pp. 154-164
    • Yoon, K.H.1    Shockey, G.R.2    Teng, R.3    Golm, G.T.4    Thakkar, P.R.5    Meehan, A.G.6
  • 36
    • 73349119110 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
    • Vilsbøll T., Rosenstock J., Yki-Järvinen H., Cefalu W.T., Chen Y., Luo E., et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12(2):167-177.
    • (2010) Diabetes Obes Metab , vol.12 , Issue.2 , pp. 167-177
    • Vilsbøll, T.1    Rosenstock, J.2    Yki-Järvinen, H.3    Cefalu, W.T.4    Chen, Y.5    Luo, E.6
  • 37
    • 33845476757 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
    • Charbonnel B., Karasik A., Liu J., Wu M., Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
    • (2006) Diabetes Care , vol.29 , pp. 2638-2643
    • Charbonnel, B.1    Karasik, A.2    Liu, J.3    Wu, M.4    Meininger, G.5
  • 38
    • 33751557143 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study
    • Rosenstock J., Brazg R., Andryuk P.J., Lu K., Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo- controlled, parallel-group study. Clin Ther 2006, 28:1556-1568.
    • (2006) Clin Ther , vol.28 , pp. 1556-1568
    • Rosenstock, J.1    Brazg, R.2    Andryuk, P.J.3    Lu, K.4    Stein, P.5
  • 39
    • 33845472504 scopus 로고    scopus 로고
    • Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
    • Sitagliptin Study 021 Group
    • Aschner P., Kipnes M.S., Lunceford J.K., Sanchez M., Mickel C., Williams-Herman D.E., Sitagliptin Study 021 Group Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29(12):2632-2637.
    • (2006) Diabetes Care , vol.29 , Issue.12 , pp. 2632-2637
    • Aschner, P.1    Kipnes, M.S.2    Lunceford, J.K.3    Sanchez, M.4    Mickel, C.5    Williams-Herman, D.E.6
  • 40
    • 84875221492 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes
    • Fonseca V., Staels B., Morgan J.D., Shentu Y., Golm G.T., Johnson-Levonas A.O., et al. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J Diabetes Complicat 2013, 27(2):177-183.
    • (2013) J Diabetes Complicat , vol.27 , Issue.2 , pp. 177-183
    • Fonseca, V.1    Staels, B.2    Morgan, J.D.3    Shentu, Y.4    Golm, G.T.5    Johnson-Levonas, A.O.6
  • 41
    • 77955573674 scopus 로고    scopus 로고
    • Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
    • DURATION-2 Study Group
    • Bergenstal R.M., Wysham C., Macconell L., Malloy J., Walsh B., Yan P., DURATION-2 Study Group, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376(9739):431-439.
    • (2010) Lancet , vol.376 , Issue.9739 , pp. 431-439
    • Bergenstal, R.M.1    Wysham, C.2    Macconell, L.3    Malloy, J.4    Walsh, B.5    Yan, P.6
  • 42
    • 39749184723 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
    • Raz I., Chen Y., Wu M., Hussain S., Kaufman K.D., Amatruda J.M., et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008, 24(2):537-550.
    • (2008) Curr Med Res Opin , vol.24 , Issue.2 , pp. 537-550
    • Raz, I.1    Chen, Y.2    Wu, M.3    Hussain, S.4    Kaufman, K.D.5    Amatruda, J.M.6
  • 43
    • 78650656671 scopus 로고    scopus 로고
    • Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
    • Arechavaleta R., Seck T., Chen Y., Krobot K.J., O'Neill E.A., Duran L., et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011, 13(2):160-168.
    • (2011) Diabetes Obes Metab , vol.13 , Issue.2 , pp. 160-168
    • Arechavaleta, R.1    Seck, T.2    Chen, Y.3    Krobot, K.J.4    O'Neill, E.A.5    Duran, L.6
  • 44
    • 84859444408 scopus 로고    scopus 로고
    • Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes
    • Wainstein J., Katz L., Engel S.S., Xu L., Golm G.T., Hussain S., et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2012, 14(5):409-418.
    • (2012) Diabetes Obes Metab , vol.14 , Issue.5 , pp. 409-418
    • Wainstein, J.1    Katz, L.2    Engel, S.S.3    Xu, L.4    Golm, G.T.5    Hussain, S.6
  • 45
    • 33845489598 scopus 로고    scopus 로고
    • Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
    • Sitagliptin Study 023 Group
    • Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., Khatami H., Sitagliptin Study 023 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006, 49(11):2564-2571.
    • (2006) Diabetologia , vol.49 , Issue.11 , pp. 2564-2571
    • Raz, I.1    Hanefeld, M.2    Xu, L.3    Caria, C.4    Williams-Herman, D.5    Khatami, H.6
  • 46
    • 84875220385 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial
    • Arjona Ferreira J.C., Corry D., Mogensen C.E., Sloan L., Xu L., Golm G.T., et al. Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis 2013, 61(4):579-587.
    • (2013) Am J Kidney Dis , vol.61 , Issue.4 , pp. 579-587
    • Arjona Ferreira, J.C.1    Corry, D.2    Mogensen, C.E.3    Sloan, L.4    Xu, L.5    Golm, G.T.6
  • 47
    • 84873465231 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes
    • Dobs A.S., Goldstein B.J., Aschner P., Horton E.S., Umpierrez G.E., Duran L., et al. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes. J Diabetes 2013, 5(1):68-79.
    • (2013) J Diabetes , vol.5 , Issue.1 , pp. 68-79
    • Dobs, A.S.1    Goldstein, B.J.2    Aschner, P.3    Horton, E.S.4    Umpierrez, G.E.5    Duran, L.6
  • 48
    • 45449105789 scopus 로고    scopus 로고
    • Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
    • Chan J.C., Scott R., Arjona Ferreira J.C., Sheng D., Gonzalez E., Davies M.J., et al. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008, 10(7):545-555.
    • (2008) Diabetes Obes Metab , vol.10 , Issue.7 , pp. 545-555
    • Chan, J.C.1    Scott, R.2    Arjona Ferreira, J.C.3    Sheng, D.4    Gonzalez, E.5    Davies, M.J.6
  • 49
    • 77952083721 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes
    • Williams-Herman D., Johnson J., Teng R., Golm G., Kaufman K.D., Goldstein B.J., et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12(5):442-451.
    • (2010) Diabetes Obes Metab , vol.12 , Issue.5 , pp. 442-451
    • Williams-Herman, D.1    Johnson, J.2    Teng, R.3    Golm, G.4    Kaufman, K.D.5    Goldstein, B.J.6
  • 50
    • 77949387699 scopus 로고    scopus 로고
    • Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
    • Sitagliptin Study 024 Group
    • Seck T., Nauck M., Sheng D., Sunga S., Davies M.J., Stein P.P., Sitagliptin Study 024 Group, et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010, 64(5):562-576.
    • (2010) Int J Clin Pract , vol.64 , Issue.5 , pp. 562-576
    • Seck, T.1    Nauck, M.2    Sheng, D.3    Sunga, S.4    Davies, M.J.5    Stein, P.P.6
  • 51
    • 84881189911 scopus 로고    scopus 로고
    • Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study
    • Strain W.D., Lukashevich V., Kothny W., Hoellinger M.J., Paldánius P.M. Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 2013, 382(9890):409-416.
    • (2013) Lancet , vol.382 , Issue.9890 , pp. 409-416
    • Strain, W.D.1    Lukashevich, V.2    Kothny, W.3    Hoellinger, M.J.4    Paldánius, P.M.5
  • 52
    • 34247874561 scopus 로고    scopus 로고
    • Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
    • Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007, 50(6):1148-1155.
    • (2007) Diabetologia , vol.50 , Issue.6 , pp. 1148-1155
    • Fonseca, V.1    Schweizer, A.2    Albrecht, D.3    Baron, M.A.4    Chang, I.5    Dejager, S.6
  • 53
    • 84863312882 scopus 로고    scopus 로고
    • Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus
    • Institution Investigators
    • Pan C., Xing X., Han P., Zheng S., Ma J., Liu J., Institution Investigators, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012, 14(8):737-744.
    • (2012) Diabetes Obes Metab , vol.14 , Issue.8 , pp. 737-744
    • Pan, C.1    Xing, X.2    Han, P.3    Zheng, S.4    Ma, J.5    Liu, J.6
  • 54
    • 41749106662 scopus 로고    scopus 로고
    • Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
    • Pan C., Yang W., Barona J.P., Wang Y., Niggli M., Mohideen P., et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet Med 2008, 25(4):435-441.
    • (2008) Diabet Med , vol.25 , Issue.4 , pp. 435-441
    • Pan, C.1    Yang, W.2    Barona, J.P.3    Wang, Y.4    Niggli, M.5    Mohideen, P.6
  • 55
    • 33847687205 scopus 로고    scopus 로고
    • Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
    • Dejager S., Razac S., Foley J.E., Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007, 39(3):218-223.
    • (2007) Horm Metab Res , vol.39 , Issue.3 , pp. 218-223
    • Dejager, S.1    Razac, S.2    Foley, J.E.3    Schweizer, A.4
  • 56
    • 44949170696 scopus 로고    scopus 로고
    • Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia
    • Scherbaum W.A., Schweizer A., Mari A., Nilsson P.M., Lalanne G., Jauffret S., et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab 2008, 10(8):675-682.
    • (2008) Diabetes Obes Metab , vol.10 , Issue.8 , pp. 675-682
    • Scherbaum, W.A.1    Schweizer, A.2    Mari, A.3    Nilsson, P.M.4    Lalanne, G.5    Jauffret, S.6
  • 57
    • 65549131200 scopus 로고    scopus 로고
    • Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
    • Bolli G., Dotta F., Colin L., Minic B., Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009, 11:589-595.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 589-595
    • Bolli, G.1    Dotta, F.2    Colin, L.3    Minic, B.4    Goodman, M.5
  • 58
    • 58149330590 scopus 로고    scopus 로고
    • Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
    • Ferrannini E., Fonseca V., Zinman B., Matthews D., Ahrén B., Byiers S., et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009, 11(2):157-166.
    • (2009) Diabetes Obes Metab , vol.11 , Issue.2 , pp. 157-166
    • Ferrannini, E.1    Fonseca, V.2    Zinman, B.3    Matthews, D.4    Ahrén, B.5    Byiers, S.6
  • 59
    • 65549109984 scopus 로고    scopus 로고
    • Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus
    • Rosenstock J., Niggli M., Maldonado-Lutomirsky M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11(6):571-578.
    • (2009) Diabetes Obes Metab , vol.11 , Issue.6 , pp. 571-578
    • Rosenstock, J.1    Niggli, M.2    Maldonado-Lutomirsky, M.3
  • 60
    • 71849095372 scopus 로고    scopus 로고
    • Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes
    • Foley J.E., Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. Horm Metab Res 2009, 41(12):905-909. 10.1055/s-0029-1234042.
    • (2009) Horm Metab Res , vol.41 , Issue.12 , pp. 905-909
    • Foley, J.E.1    Sreenan, S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.